Medical weight loss, physician-led, built to last.
Tirzepatide, semaglutide, peptide adjuncts, hormone optimization, and a lean-mass-preservation architecture — designed and monitored by Dr. Joshua Hare, DO. The drug is one tool. The system is the result.
Request a consultation How the Program WorksThe most effective weight-loss medications ever made. Used the right way.
The current generation of GLP-1 / GIP medications produces 14–22% mean weight loss in Phase 3 trials. The next generation — retatrutide — is reading out at 28.7%. These are the most effective metabolic interventions ever made widely available.
And yet the real-world failure mode of weight-loss medication is not that the drugs don't work. It's that they're prescribed without an architecture beneath them — without lab work, without hormone optimization, without lean-mass preservation, without an exit plan. Two-thirds of weight is regained within twelve months of stopping unless that architecture is built.
The Limitless weight loss program is the architecture. The medication is one component of it.
What every Limitless weight-loss program contains.
Whether the patient is on tirzepatide, semaglutide, or no drug at all, these four pillars are non-negotiable. Drugs amplify what's underneath them. Without the pillars, drugs lose their leverage.
Drug selection on labs
Tirzepatide for most. Semaglutide when CV protection is the priority. Drug choice driven by labs, comorbidities, and goals — not whichever drug the loudest voice is recommending.
Hormone optimization
Testosterone, thyroid, cortisol screened and treated. Untreated hypogonadism caps weight loss in men. Subclinical hypothyroidism slows everything in women.
Lean-mass protection
Protein 1.6–2.2 g/kg. Resistance training 3×/week minimum. Creatine 5g daily. Without this, 25–35% of GLP-1 weight loss is lean tissue — unacceptable for longevity.
Exit + maintenance plan
Discontinuation strategy designed at intake — taper protocols, maintenance dosing, lifestyle anchors. We treat GLP-1s as ongoing therapy unless you choose otherwise.
The drugs we prescribe, plain language.
Three drugs dominate the conversation in 2026. We prescribe two of them today, and we'll add the third when it launches. Here is the honest breakdown.
Tirzepatide
Mounjaro (T2D) and Zepbound (obesity, OSA). Dual GLP-1 + GIP agonist. The current standard of care for most weight-loss patients. SURMOUNT-5 confirmed superiority over semaglutide head-to-head. Also approved for obstructive sleep apnea.
Semaglutide
Ozempic (T2D) and Wegovy (obesity). Single GLP-1 agonist. Prescribed when cardiovascular protection is the priority — the SELECT trial demonstrated 20% reduction in major adverse cardiovascular events in patients with established CV disease.
Retatrutide
Eli Lilly's triple agonist (GLP-1 + GIP + glucagon). TRIUMPH-4 produced the highest weight-loss figure ever in a Phase 3 obesity trial. Investigational as of May 2026; not legally compoundable. We do not source from gray markets. When approved, it joins the formulary.
For the full landscape — including CagriSema, orforglipron, and survodutide — read our 2026 GLP-1 landscape primer.
What we layer alongside the drug.
The peptide formulary is what differentiates a Limitless weight-loss program from a typical telehealth GLP-1 prescription. These are the most-used adjuncts:
- Tesamorelin — FDA-approved GHRH analog. Targets visceral fat specifically and supports the GH axis that preserves lean mass during a GLP-1 cut. Our standing lean-mass-insurance layer when scale weight is moving but composition matters.
- MOTS-c — Mitochondrial peptide that activates AMPK. Useful for metabolic plateau, post-GLP-1 maintenance, and longevity-first patients. Prescribed only through licensed 503A pharmacies.
- Sermorelin (or ipamorelin where formulary permits) — Pulsatile GH-axis support. Restores natural GH rhythm, improves sleep and recovery, supports lean mass during the cut. CJC-1295 is not in our standing menu — see our GH-axis brief.
- NAD+ (IV + SubQ) — Dr. Hare's signature longevity intervention. NAD+ stores deplete during caloric restriction; loading and maintenance protect cellular energy throughout the program.
- Testosterone optimization (men) — Hypogonadal men consistently lose more body fat and preserve more lean mass on GLP-1 therapy than untreated peers.
- BHRT (women) — Estradiol, progesterone, and (for many) testosterone optimized. Perimenopausal weight gain is largely a hormone story; treating the hormones is often more effective than treating the weight.
- BPC-157 + TB-500 — Recovery and tissue-repair stack. Keeps you training when resistance volume increases.
Here is the part most GLP-1 marketing leaves out: 25–35% of the weight lost on a GLP-1 alone is lean tissue — muscle and bone you spend the rest of your life trying to get back. A lighter, weaker, more fragile version of you is not the goal. Tesamorelin is the pharmacologic half of how we protect against that: the FDA-approved GHRH analog supports your own growth-hormone axis to preserve lean mass while specifically reducing visceral fat. The 2026 pooled meta-analysis — −27.7 cm² VAT and +1.42 kg lean mass — is exactly that profile. It is why a Limitless GLP-1 program is a body-composition program, not a scale program.
The lean-mass evidence on GLP-1s → · What the 2026 tesamorelin meta-analysis shows →
From first call to lasting result — five steps.
Consultation
60-minute new-patient visit with Dr. Hare. History, goals, prior labs, contraindications. We map your protocol — not a template.
Baseline labs
CMP, A1c, fasting insulin, lipids, hormones (sex + thyroid + cortisol), hs-CRP, vitamin D, B12. Body composition (DEXA or InBody).
Protocol design
Drug selection, hormone correction, peptide adjuncts, training and protein architecture, supplement plan. Documented in the portal.
Cycle and monitor
4-week tolerability check. 12-week labs and dose decision. 24-week full review. Adjust on data, not vibes.
One year out, we make the maintenance decision together — taper, hold, or continue — based on results, comorbidities, and goals. The program is built to graduate you, not to keep you on therapy forever.
The quick eligibility answer.
FDA-labeled criteria for the obesity indication of Wegovy and Zepbound:
- BMI ≥ 30, or
- BMI ≥ 27 with at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease.
Tirzepatide is also FDA-approved for obstructive sleep apnea in adults with obesity. Semaglutide is approved for cardiovascular event reduction in patients with established CV disease.
We deliberately decline to prescribe for patients with personal/family history of medullary thyroid carcinoma or MEN-2, active pancreatitis, severe gastroparesis, active eating disorders, pregnancy or planned pregnancy, BMI < 25 with no metabolic disease, or patients seeking short-term cosmetic loss without commitment to ongoing therapy and lifestyle architecture.
For the full candidate-selection framework — including special populations, screening labs, and the patients we ask to start somewhere else — read our "Are You a Candidate?" guide.
Read more — five articles on weight loss in 2026.
Dr. Hare's deep-dive series on the GLP-1 / GIP / glucagon landscape, anchored to the latest Phase 3 data. Educational, not promotional.
Retatrutide in 2026
Phase 3 TRIUMPH-4 produced 28.7% mean weight loss. Mechanism, FDA timeline, and what it changes about how we approach weight loss.
Tirzepatide vs. Semaglutide
SURMOUNT-5 (NEJM 2025) — the only randomized head-to-head trial. 20.2% vs. 13.7%. How to choose between Zepbound and Wegovy.
The 2026 GLP-1 landscape
Every drug, every generation. Semaglutide to retatrutide, plus orforglipron, CagriSema, survodutide.
Beyond GLP-1
Tesamorelin, MOTS-c, hormone optimization, lean-mass protection. The toolkit drugs alone cannot replace.
Are you a candidate?
BMI thresholds, contraindications, screening labs, monitoring. The patients we deliberately decline to prescribe for.
Retatrutide beyond weight loss
86% liver fat reduction, 14 mmHg BP drops, 2.0% A1c reduction, plus emerging cognitive and addiction signals. The secondary endpoint story.
Dr. Hare's daily protocol
The integrated regimen Dr. Hare runs himself — sleep, training, peptides, hormones, labs. Not medical advice. A working example.
Book a consultation
The fastest path from "I'm thinking about this" to "I have a plan." 60-minute new-patient visit with Dr. Hare. In-person in Dalton or telehealth across Georgia.
Weight loss at Limitless, asked and answered.
- How much weight will I lose?
- Real-world response averages 75–85% of trial response. On tirzepatide with a full Limitless protocol, most patients lose 15–22% of body weight over 12–18 months. Individual response varies considerably based on labs, hormones, sleep, training, and adherence.
- Do you take insurance?
- Insurance covers semaglutide and tirzepatide variably depending on plan, BMI, and diabetes status. The Limitless clinical management — consultation, comprehensive labs, peptide adjuncts, hormone optimization, follow-up — is membership-based or per-visit, not covered by insurance.
- What does this cost out-of-pocket?
- Drug cost is paid through your pharmacy. Manufacturer savings programs apply. Limitless quotes the clinical management transparently during consultation. We don't markup compounded medications to patients.
- Can I be on this and on TRT (or BHRT)?
- Yes — and many of our patients are. Hormone optimization usually amplifies GLP-1 response. We coordinate everything in one chart.
- Do I have to inject?
- For tirzepatide and semaglutide, yes — once weekly subcutaneous, similar to insulin in technique. We train you in clinic. An oral GLP-1 (orforglipron) is anticipated to launch in 2026–2027 with significantly less weight loss but no injection.
- Will I have to take this forever?
- Most patients stay on therapy long-term, similar to a statin or thyroid medication. Some patients taper to a maintenance dose; some discontinue entirely with strong lifestyle architecture. Your exit strategy is designed at intake — and revisited every six months.
- What if retatrutide gets approved next year?
- You stay on what's working until then, and we evaluate switching when retatrutide launches. Anticipated FDA approval is late 2027 or early 2028. We do not recommend waiting.
- What if I'm not in Dalton?
- New-patient consultation is in person at our Dalton clinic. Subsequent visits and management can be telehealth across the state of Georgia. Patients regularly travel from Chattanooga, Knoxville, Atlanta, Birmingham, and Asheville for care.
Build the system. The drug is just one tool.
Now open · Dalton, GA · By appointment. The first step is a 60-minute new-patient consultation with Dr. Hare at the Dalton clinic.
Request a consultation Call Dalton IPC 706-847-0826